Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine

Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox propo...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2000-11, Vol.31 (5), p.1234-1239
Main Authors: Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L. F., Weverling, G. J.
Format: Article
Language:English
Subjects:
AIDS
antiretroviral therapy
Antiretrovirals
aspartate aminotransferase
Chronic hepatitis
Hepatitis antigens
Hepatotoxicity
HIV
HIV/AIDS
Human immunodeficiency virus 1
Infections
liver enzyme elevation
Medications
Predisposing factors
RNA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243
cites cdi_FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243
container_end_page 1239
container_issue 5
container_start_page 1234
container_title Clinical infectious diseases
container_volume 31
creator Gisolf, E. H.
Dreezen, C.
Danner, S. A.
Weel, J. L. F.
Weverling, G. J.
description Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3–23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5–16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by>50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.
doi_str_mv 10.1086/317449
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17890608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4461414</jstor_id><oup_id>10.1086/317449</oup_id><sourcerecordid>4461414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243</originalsourceid><addsrcrecordid>eNp1kM9OFTEUxidEEhDkCVzUjbvRnumf6SyVCPcaouSiQtg0tT3VwmV6aTtX7s6H8Al9EoeMgRWr75x8v5yc76uqA6BvgCr5lkHLebdV7YJgbS1FB8_GmQpVc8XUTvU85ytKARQVu9VmEfI1OTK2xJSJj4nMcGVKLPEu2FA2JPRkNv9Ww9_ff-a9R1vQkVNTAvYlkwVaDOvQ_yCLUGJv1iER0ztyZm6HMK2_QvlJ4qRxKOSsmPXgQo_71bY3y4wv_ute9fXow5fDWX3y-Xh--O6ktkx2pbYOGDpLwRpJfduB94AKbYPfwTcOuaDO0UYpJS03QjSC-TFbK1VHO9dwtle9nu6uUrwdMBd9E7LF5dL0GIesoR1JSdUjaFPMOaHXqxRuTNpooPq-WT01O4KvJjAOq6eZlxNzlcdmHyjOJXC4f6qe7JAL3j3YJl1r2bJW6NnFpT4-7Rbvz8VH_Yn9A4lQj80</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17890608</pqid></control><display><type>article</type><title>Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine</title><source>Oxford Journals Online</source><source>JSTOR Archival Journals</source><creator>Gisolf, E. H. ; Dreezen, C. ; Danner, S. A. ; Weel, J. L. F. ; Weverling, G. J.</creator><creatorcontrib>Gisolf, E. H. ; Dreezen, C. ; Danner, S. A. ; Weel, J. L. F. ; Weverling, G. J. ; for the Prometheus Study Group</creatorcontrib><description>Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3–23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5–16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by&gt;50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/317449</identifier><language>eng</language><publisher>The University of Chicago Press</publisher><subject>AIDS ; antiretroviral therapy ; Antiretrovirals ; aspartate aminotransferase ; Chronic hepatitis ; Hepatitis antigens ; Hepatotoxicity ; HIV ; HIV/AIDS ; Human immunodeficiency virus 1 ; Infections ; liver enzyme elevation ; Medications ; Predisposing factors ; RNA</subject><ispartof>Clinical infectious diseases, 2000-11, Vol.31 (5), p.1234-1239</ispartof><rights>Copyright 2000 The Infectious Diseases Society of America</rights><rights>2000 by the Infectious Diseases Society of America 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243</citedby><cites>FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4461414$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4461414$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids></links><search><creatorcontrib>Gisolf, E. H.</creatorcontrib><creatorcontrib>Dreezen, C.</creatorcontrib><creatorcontrib>Danner, S. A.</creatorcontrib><creatorcontrib>Weel, J. L. F.</creatorcontrib><creatorcontrib>Weverling, G. J.</creatorcontrib><creatorcontrib>for the Prometheus Study Group</creatorcontrib><title>Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3–23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5–16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by&gt;50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.</description><subject>AIDS</subject><subject>antiretroviral therapy</subject><subject>Antiretrovirals</subject><subject>aspartate aminotransferase</subject><subject>Chronic hepatitis</subject><subject>Hepatitis antigens</subject><subject>Hepatotoxicity</subject><subject>HIV</subject><subject>HIV/AIDS</subject><subject>Human immunodeficiency virus 1</subject><subject>Infections</subject><subject>liver enzyme elevation</subject><subject>Medications</subject><subject>Predisposing factors</subject><subject>RNA</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp1kM9OFTEUxidEEhDkCVzUjbvRnumf6SyVCPcaouSiQtg0tT3VwmV6aTtX7s6H8Al9EoeMgRWr75x8v5yc76uqA6BvgCr5lkHLebdV7YJgbS1FB8_GmQpVc8XUTvU85ytKARQVu9VmEfI1OTK2xJSJj4nMcGVKLPEu2FA2JPRkNv9Ww9_ff-a9R1vQkVNTAvYlkwVaDOvQ_yCLUGJv1iER0ztyZm6HMK2_QvlJ4qRxKOSsmPXgQo_71bY3y4wv_ute9fXow5fDWX3y-Xh--O6ktkx2pbYOGDpLwRpJfduB94AKbYPfwTcOuaDO0UYpJS03QjSC-TFbK1VHO9dwtle9nu6uUrwdMBd9E7LF5dL0GIesoR1JSdUjaFPMOaHXqxRuTNpooPq-WT01O4KvJjAOq6eZlxNzlcdmHyjOJXC4f6qe7JAL3j3YJl1r2bJW6NnFpT4-7Rbvz8VH_Yn9A4lQj80</recordid><startdate>20001115</startdate><enddate>20001115</enddate><creator>Gisolf, E. H.</creator><creator>Dreezen, C.</creator><creator>Danner, S. A.</creator><creator>Weel, J. L. F.</creator><creator>Weverling, G. J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20001115</creationdate><title>Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine</title><author>Gisolf, E. H. ; Dreezen, C. ; Danner, S. A. ; Weel, J. L. F. ; Weverling, G. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>AIDS</topic><topic>antiretroviral therapy</topic><topic>Antiretrovirals</topic><topic>aspartate aminotransferase</topic><topic>Chronic hepatitis</topic><topic>Hepatitis antigens</topic><topic>Hepatotoxicity</topic><topic>HIV</topic><topic>HIV/AIDS</topic><topic>Human immunodeficiency virus 1</topic><topic>Infections</topic><topic>liver enzyme elevation</topic><topic>Medications</topic><topic>Predisposing factors</topic><topic>RNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gisolf, E. H.</creatorcontrib><creatorcontrib>Dreezen, C.</creatorcontrib><creatorcontrib>Danner, S. A.</creatorcontrib><creatorcontrib>Weel, J. L. F.</creatorcontrib><creatorcontrib>Weverling, G. J.</creatorcontrib><creatorcontrib>for the Prometheus Study Group</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gisolf, E. H.</au><au>Dreezen, C.</au><au>Danner, S. A.</au><au>Weel, J. L. F.</au><au>Weverling, G. J.</au><aucorp>for the Prometheus Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2000-11-15</date><risdate>2000</risdate><volume>31</volume><issue>5</issue><spage>1234</spage><epage>1239</epage><pages>1234-1239</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in 208 HIV-infected patients, by use of the Cox proportional hazard model. Eighteen patients (9%) developed LEE during the 48-week follow-up. Multivariate analysis, adjusted for baseline levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), showed that hepatitis B surface antigen (HBsAg) positivity (relative risk [RR], 8.8; 95% confidence interval [CI], 3.3–23.1) and the use of stavudine (RR, 4.9; 95% CI, 1.5–16.0) were the only significant risk factors for developing LEE. After LEE occurred, ALT and AST concentrations decreased by&gt;50% in 13 of 14 patients who continued ARVT during LEE. In this study, it appeared safe to continue ARVT during LEE; however, more data from larger studies are required to confirm this finding.</abstract><pub>The University of Chicago Press</pub><doi>10.1086/317449</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2000-11, Vol.31 (5), p.1234-1239
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_17890608
source Oxford Journals Online; JSTOR Archival Journals
subjects AIDS
antiretroviral therapy
Antiretrovirals
aspartate aminotransferase
Chronic hepatitis
Hepatitis antigens
Hepatotoxicity
HIV
HIV/AIDS
Human immunodeficiency virus 1
Infections
liver enzyme elevation
Medications
Predisposing factors
RNA
title Risk Factors for Hepatotoxicity in HIV-1—Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A46%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20Factors%20for%20Hepatotoxicity%20in%20HIV-1%E2%80%94Infected%20Patients%20Receiving%20Ritonavir%20and%20Saquinavir%20with%20or%20without%20Stavudine&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Gisolf,%20E.%20H.&rft.aucorp=for%20the%20Prometheus%20Study%20Group&rft.date=2000-11-15&rft.volume=31&rft.issue=5&rft.spage=1234&rft.epage=1239&rft.pages=1234-1239&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/317449&rft_dat=%3Cjstor_proqu%3E4461414%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-cd13edc01ca60f791ff1e8ec2eb1f2de450dd028886c4a55253f118768909d243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17890608&rft_id=info:pmid/&rft_jstor_id=4461414&rft_oup_id=10.1086/317449&rfr_iscdi=true